# Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

> **NCT05289830** · PHASE2 · TERMINATED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma
- Periampullary Cancer

## Interventions

- **DRUG:** Escitalopram
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05289830
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-05
- **Primary completion:** 2023-08-27
- **Final completion:** 2023-08-27
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05289830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05289830, "Escitalopram to Placebo in Patients With Localized Pancreatic Cancer". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT05289830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*